10-K: Castle Biosciences Achieves Profitability in 2024 Driven by Strong Revenue Growth, Faces Headwinds from Pending Medicare Coverage Change for DecisionDx-SCC

Castle Biosciences reported a return to profitability and a 51% revenue increase for the fiscal year 2024, fueled by its dermatology and gastroenterology tests, though future results face uncertainty due to an impending Medicare non-coverage decision for its DecisionDx-SCC test.

Summary

• Castle Biosciences, a molecular diagnostics company, reported its financial results for the fiscal year ended December 31, 2024.
• The company offers tests aiding in the diagnosis and treatment of dermatologic cancers (DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma), Barrett's esophagus (TissueCypher), uveal melanoma (DecisionDx-UM), and guiding mental health treatment (IDgenetix).
• Total net revenues for 2024 reached $332.1 million, a 51.1% increase compared to $219.8 million in 2023, driven by growth across its portfolio, particularly DecisionDx-SCC and TissueCypher.
• The company achieved net income of $18.2 million in 2024, compared to a net loss of $57.5 million in 2023.
• Total test reports delivered increased 36.4% to 96,071 in 2024 from 70,429 in 2023.
• DecisionDx-Melanoma reports grew 8.0% to 36,008, DecisionDx-SCC reports grew 42.9% to 16,348, and TissueCypher reports grew 130.3% to 20,956.
• IDgenetix reports increased 57.0% to 17,151, however, the company revised its commercial strategy for IDgenetix in late 2024 due to underperformance and expects volumes to decrease in 2025.
• A significant challenge looms as Medicare Administrative Contractor Novitas finalized a Local Coverage Determination (LCD) effective April 24, 2025, which is expected to result in non-coverage for DecisionDx-SCC tests, impacting future revenues.
• The company is advancing its pipeline, including a test for moderate-to-severe atopic dermatitis (AD), with preliminary positive data announced and a target launch by the end of 2025.
• Castle Biosciences ended the year with $119.7 million in cash and cash equivalents and $173.4 million in marketable investment securities.
• In March 2024, the company secured a $35 million credit facility, drawing $10 million initially, primarily for its new headquarters construction.
• The company received a subpoena from the HHS OIG in February 2024 regarding billing practices under federal healthcare programs.

Sentiment

Score: 6

Explanation: The company achieved significant revenue growth and profitability in 2024, with positive operating cash flow. However, the impending loss of Medicare coverage for a key revenue driver (DecisionDx-SCC) casts a significant shadow over future performance, and the IDgenetix outlook is weak, creating substantial uncertainty despite positive operational metrics and pipeline progress.

Positives

• Reported significant revenue growth of 51.1% for the full year 2024.
• Returned to profitability with $18.2 million in net income for FY2024.
• Generated substantial positive operating cash flow of $64.9 million in FY2024.
• Gross margin improved to 78.5% in FY2024 from 75.4% in FY2023.
• Strong volume growth was observed in key tests like DecisionDx-SCC (up 42.9%) and TissueCypher (up 130.3%).
• DecisionDx-Melanoma test report volume continued to grow, increasing by 8.0%.
• Progress made in the pipeline with promising preliminary data for the atopic dermatitis test.
• Maintained ADLT status for all five core MAAA tests, supporting Medicare reimbursement structures.
• Successfully managed TissueCypher operational scaling, completing backlog and resuming normal order acceptance.
• Secured debt financing to support strategic initiatives like the new headquarters construction.
• Employee engagement score of 85% reported as higher than the healthcare benchmark average.

Negatives

• Medicare contractor Novitas finalized a negative coverage decision for DecisionDx-SCC, effective April 24, 2025, which is expected to significantly impact future revenue.
• Medicare contractor Palmetto/Noridian also finalized a negative coverage decision for DecisionDx-SCC, effective August 18, 2024.
• Revenue remains concentrated, with Medicare accounting for 47% and one commercial payor for 15% in FY2024.
• The company has a history of losses, with an accumulated deficit of $200.1 million as of December 31, 2024.
• The commercial strategy for the IDgenetix test was revised due to underperformance, with volume and revenue expected to decrease in 2025.
• Received a subpoena from the HHS OIG regarding federal healthcare program billing practices, creating legal uncertainty and potential costs.
• Billing and reimbursement processes remain complex and subject to denials, audits, and recoupments.
• Operating expenses increased by 12.4% in FY2024, driven by investments in growth.
• The estimated useful life of the IDgenetix intangible asset was significantly shortened, resulting in increased future amortization expense.

Risks

• The finalized negative Medicare coverage decisions for DecisionDx-SCC pose a significant risk to future revenue and profitability.
• Continued reliance on reimbursement from a small number of third-party payors, particularly Medicare, makes the company vulnerable to policy changes.
• Potential changes in FDA regulation or enforcement discretion regarding Laboratory Developed Tests (LDTs), despite the recent final rule potentially grandfathering existing tests, could impact future products or modifications.
• Failure to achieve or maintain broad commercial payor coverage and adequate reimbursement rates for current and future tests could hinder growth.
• The diagnostic testing industry is highly competitive and subject to rapid technological change, potentially rendering current products obsolete.
• Dependence on third parties for sample collection and sole or limited suppliers for critical reagents and equipment creates operational risks.
• Inability to successfully develop and commercialize new pipeline products, like the AD test, represents a risk to long-term growth.
• Potential failure to effectively manage growth and integrate past or future acquisitions could strain resources and impact performance.
• Cybersecurity threats pose a risk to sensitive patient data, intellectual property, and operational continuity.
• The ongoing HHS OIG investigation could result in significant penalties, reputational harm, or operational changes.
• General economic conditions, inflation, and geopolitical events could adversely affect operations, costs, and demand.
• Intellectual property protection may be insufficient, and the company could face infringement claims.
• The company may need to raise additional capital in the future, which might be dilutive or carry restrictive covenants.

Future Outlook

Castle Biosciences anticipates continued investment in research and development, clinical studies, and commercial activities to support existing products and advance its pipeline, including the targeted launch of its atopic dermatitis test by the end of 2025. However, the company expects the finalized Medicare non-coverage decision for DecisionDx-SCC, effective April 24, 2025, to adversely impact future revenues and operating results. Additionally, following a commercial strategy shift for IDgenetix, decreased test report volumes and revenues are expected for this test in 2025. The company plans to complete construction of its new corporate headquarters in early 2026. While management believes current liquidity is sufficient for the next 12 months, additional capital may be sought for longer-term objectives.

Management Comments

• The company's vision is to transform disease management by keeping people first: patients, clinicians, employees and investors.
• Maintaining commercial success requires generating ongoing evidence to support clinician adoption, reimbursement success and guideline inclusion.
• New product development involves a lengthy and complex process, requiring scientific diligence, stringent clinical protocols, machine learning expertise, proprietary algorithms and significant investments.
• Billing for products is complex and requires substantial time and resources to collect payment.
• The company relies on limited or sole suppliers for some reagents, equipment, chips and other materials.
• Estimates of the total addressable market (TAM) for products have not been established with precision and may be smaller than estimated.
• The FDA's final rule on LDTs is expected to have no material impact on the company's existing test offerings as they were marketed before May 6, 2024 and are NYSDOH approved.
• Management believes existing cash, marketable securities, and anticipated cash from sales will be sufficient to fund operations for at least the next 12 months.
• The company expects operating expenses will increase substantially over time due to planned investments in commercialization, R&D, pipeline development, and operational expansion.

Industry Context

Castle Biosciences operates within the dynamic molecular diagnostics sector, focusing on providing actionable genomic and proteomic information for personalized medicine, primarily in oncology and mental health. The industry faces evolving regulatory landscapes, particularly concerning Laboratory Developed Tests (LDTs), with the recent FDA final rule aiming to increase oversight, although grandfathering provisions may apply to existing tests like Castle's. Payor scrutiny remains high, demanding robust clinical utility and economic value data for reimbursement. Castle competes with large reference laboratories and specialized diagnostic companies, differentiating itself through its multi-analyte algorithmic approach (MAAA) and extensive publication record.

Comparison to Industry Standards

• Castle Biosciences' focus on proprietary MAAA tests with ADLT status (DecisionDx-Melanoma, DecisionDx-UM, MyPath Melanoma, DecisionDx-SCC, TissueCypher) differentiates it from competitors offering less complex or non-ADLT tests.
• The company's emphasis on peer-reviewed publications (approximately 157 across its portfolio) to demonstrate clinical validity and utility aligns with industry best practices for gaining clinician adoption and payor coverage.
• Competition for DecisionDx-UM includes a LabCorp subsidiary and academic labs; Castle asserts superior clinical data.
• IDgenetix competes directly with established pharmacogenomic tests like Myriad Genetics' GeneSight and Genomind's PGx test.
• DecisionDx-Melanoma faces competition from traditional staging methods and newer tests from companies like SkylineDx/Tempus/Quest and AMLo/Avero.
• TissueCypher competes against traditional pathology assessments and tests from companies like Previse, Interpace Diagnostics, and Lucid Diagnostics.
• The impending Medicare non-coverage for DecisionDx-SCC by Novitas represents a significant deviation from the positive coverage status held by the company's other core tests and potentially puts it at a disadvantage compared to competitors unaffected by this specific LCD.
• The company's reported employee engagement score of 85% exceeds the stated healthcare industry benchmark average of 70% for 2024.

Legal Proceedings

• On February 1, 2024, the company received a subpoena from the United States Department of Health and Human Services, Office of Inspector General.
• The subpoena seeks documents and information concerning claims submitted for payment under federal healthcare programs, primarily relating to interactions with medical providers and billing for the company's tests from January 1, 2015, through February 1, 2024.
• The company is cooperating with the government's request and is unable to predict the outcome or estimate potential loss.
• No claims have been made against the company at this time related to this subpoena.

Related Party Transactions

• The company employs three children and a brother-in-law of CEO Derek J. Maetzold in non-officer positions.
• The company employs two children and a son-in-law of COO Kristen M. Oelschlager in non-officer positions.
• The company employs the son of CCO Tobin W. Juvenal in a non-officer position.
• Certain officers (Maetzold, Stokes, Juvenal, Oelschlager), directors (Maetzold, Bradbury), and their family members held securities in AltheaDx and received consideration upon its acquisition in April 2022.

Stakeholder Impact

• Shareholders face potential stock price volatility due to reimbursement uncertainty (DecisionDx-SCC), regulatory changes (LDTs), and the HHS OIG investigation.
• Shareholders benefited from the return to profitability in 2024 but face dilution risk from potential future equity raises and ongoing stock compensation.
• Employees benefit from compensation packages including equity, but face uncertainty related to the IDgenetix commercial shift and potential impacts from the SCC reimbursement issue.
• Clinicians and patients rely on the accuracy and timely reporting of tests; potential loss of Medicare coverage for DecisionDx-SCC could limit patient access or increase out-of-pocket costs.
• Payors (Medicare, commercial insurers) are impacted by the cost and clinical utility data presented for reimbursement decisions and face ongoing negotiations regarding coverage and rates.

Next Steps

• Continue commercialization efforts for existing tests.
• Continue clinical studies to support existing products and pipeline development.
• Advance the inflammatory skin disease (AD) pipeline test towards an expected launch by the end of 2025.
• Manage the impact of the finalized Medicare non-coverage decision for DecisionDx-SCC.
• Continue construction of the new corporate headquarters, expected to be completed in early 2026.
• Continue to pursue positive coverage and reimbursement decisions from commercial payors.
• Monitor and respond to the HHS OIG subpoena received in February 2024.

Key Dates

Keywords

Castle Biosciences, CSTL, molecular diagnostics, dermatology oncology, cutaneous melanoma, squamous cell carcinoma, Barrett's esophagus, uveal melanoma, pharmacogenomics, mental health, gene expression profile, GEP, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, MyPath Melanoma, DecisionDx-UM, IDgenetix, Medicare reimbursement, LDT, laboratory developed test, ADLT, clinical diagnostics, cancer diagnostics, FDA regulation, HHS OIG subpoena